SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
| Date: | Wednesday, May 17, 2017 | ||
| Forum: | Panel Discussion on Gene Therapy and Gene Editing | ||
| Time: | 4:40 p.m. ET | ||
| Location: | Las Vegas |
UBS Global Healthcare Conference
| Date: | Monday, May 22, 2017 | ||
| Forum: | Company Presentation and Breakout Session | ||
| Time: | 8:00 a.m. ET | ||
| Location: | New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Cristi Barnett Editas Medicine, Inc. (617) 401-0113 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
